Opinion
Video
Robert Gabbay, MD, PhD, discusses research showing that early intervention with a recent FDA-approved therapy can delay the onset of type 1 diabetes by an average of 2-3 years.
Polatuzumab Vedotin: Review Spotlights Its Use, Promise in DLBCL
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
AYA With T1D Have Suboptimal Glucose Control
Frameworks for Advancing Health Equity: Urban Health Outreach
Different Roads, Same Goal: Dr Joseph Mikhael Explores Early R/R Multiple Myeloma Treatment Strategies in the US, Europe
Quadruplets and Fast CARs: “Breathtaking” New Data for Frontline MM Treatment